Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CENTRIC: Cilengitide in Newly Diagnosed Glioblastoma
NCT00689221Phase 3Completed
- Sponsor
- EMD Serono
- Start
- Sep 2008
- Primary completion
- Nov 2012
- Modality
- Small Molecules, Modified Peptides
- Countries
- 2
01
Overview
A Phase 3 trial of cilengitide in glioblastoma (GBM), sponsored by EMD Serono. Started Sep 2008; status: completed.
02
Drugs
cilengitide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00689221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00689221.